AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus
14-Feb-2022 -
AiCuris Anti-infective Cures AG (AiCuris) and Hybridize Therapeutics (Hybridize) announced that they have entered into a worldwide licensing agreement for Hybridize’s BK virus (BKV) program. The licensed program is based on a novel RNA-based therapeutic approach developed by Hybridize.
Under the ...
kidney transplantations
nephropathy
RNA therapeutics
+2